养殖ETF（159865）跟踪的是中证畜牧指数（930707），该指数从沪深市场中选取业务涉及畜禽养殖、 饲料加工等领域的上市公司证券作为指数样本，以反映畜牧业相关上市公司证券的整体表现。中证畜牧 指数覆盖了畜禽养殖、饲料及动保等多个细分领域，具有较强的行业代表性。 （文章来源：每日经济新闻） 根据wind数据，养殖ETF（159865）盘中流入2000万份，盘中净流入100万份，资金抢筹养殖资产。 财通证券表示，猪价延续上行。供应缩量，仔猪交易增加，二育入场放缓，供需博弈猪价上行。预计， 供应压力释放，叠加政策引导，产能去化或加速。 ...

Group 1: Investment Overview - The company has established a specialized pharmaceutical industry investment fund in collaboration with professional investment institutions, aiming to enhance its industrial investment ecosystem and core competitiveness [2][5]. - The total committed capital for the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [2][5]. - The fund is named "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)" and has completed its business registration and regulatory filing [3][4]. Group 2: Fund Progress - As of the announcement date, the fund has successfully raised the initial capital of RMB 10 million [3][4]. - The fund's operational scope includes equity investment and venture capital, specifically targeting unlisted companies [3][4]. Group 3: Impact on the Company - The fund will primarily invest in innovative drugs, medical aesthetics, health, animal protection, and other sectors aligned with the company's strategic development [5]. - This initiative is expected to improve the efficiency of the company's idle capital, reduce investment risks, and create reasonable returns for shareholders [5]. Group 4: Clinical Trial Approval - The company's wholly-owned subsidiary has received FDA approval for the clinical trial of the drug HDM2017, which targets advanced malignant solid tumors [9][10]. - HDM2017 is a novel antibody-drug conjugate developed by the subsidiary, showing promising preclinical results in treating various cancers [11][12]. - The approval marks a significant advancement in the drug's development process, enhancing the company's competitiveness in the oncology field [12].